to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
Entrepreneurs are the cream of the crop – the best innovators in the economy. So why are such smart people overpaying for health insurance?
Healthcare innovators can benefit from a trio of grant awards from the National Institutes of Health. Read more about how the NIH is helping innovators in the life sciences field.
Life sciences business owners are seeing a modest rise in venture capital funds – no mean feat in this economy. But one big communications mistake will take you and your firm out of the running.
Can "boom and bust" cycles exist in the venture funding market? You bet they can. And recent data from the chemical sector is a great example of how and why.
There's stability and then there's outright growth. For healthcare business owners looking for angel funding, they'll have to accept the former and wait some more on the latter. But at least it's progress.
In a venture funding climate seeking large returns, thousands of potentially successful entrepreneurial startups can't get the financing they need to make a difference in the economy and in the culture. The problem isn't a new one, but it is a damaging one.
As year-end approaches and entrepreneurs regroup to figure out financing options for 2012, it's a good time to take a look at the two major sources of new business funding -- angel investing versus venture capital.
Local investing could be the answer to the problem of dealing with big banks and the way they do business. Read more about this funding alternative for startups.
Would you, the healthcare startup owner, accept $50,000 in funding in exchange for a 7 percent equity stake in your business? That's the question a Chicago-based healthcare seed accelerator is asking healthcare entrepreneurs. And pretty soon, we'll see how they answer that question.
Small biotech companies may have the feeling that venture capital firms are avoiding small life sciences firms like the plague. But maybe not for long -- if Washington has anything to say about it.
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.